Search research articles
Contact Us
Filters
Showing results (11-20 of 21) with videos related to
Page
of 3
Sort By:
Transplantation Proceedings
|
December 28, 2021
Can Donor-Derived Cell-Free DNA Detect Graft-Versus-Host Disease in Solid Organ Transplantation: A Case Report
Michael D Williams, Joshua Thomas, Agne Paner, et al.
Hemasphere
|
March 2, 2023
Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-related Quality of Life for Patients With Relapsed/Refractory Multiple Myeloma: Final Data From the Phase 2 ELOQUENT-3 Trial
Katja Weisel, Meletios A Dimopoulos, Jesús San-Miguel, et al.
Current Medical Research and Opinion
|
May 15, 2024
Panel Interview of ONcology practices with Emergent Experience of teclistamab in the Real world: the TecPIONEER Study
Benjamin A Derman, Meaghan Roach, Dee Lin, et al.
Investigational New Drugs
|
March 4, 2020
Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma
Eric K Rowinsky, Agne Paner, Jesus G Berdeja, et al.
Journal of Clinical Apheresis
|
June 10, 2020
Trends in the use of therapeutic plasma exchange in multiple myeloma
Binod Dhakal, Sophie Miller, Lisa Rein, et al.
NPJ Genomic Medicine
|
March 18, 2021
Non-secretory multiple myeloma with unusual TFG-ALK fusion showed dramatic response to ALK inhibition
Ashiq Masood, Trevor Christ, Samia Asif, et al.
Cancers
|
April 14, 2025
Real-World Evidence Evaluating Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Systematic Literature Review
Benjamin Derman, Carlyn Tan, Ian Steinfield, et al.
Journal of Medical Economics
|
June 11, 2025
Cost per responder for teclistamab and elranatamab in relapsed or refractory multiple myeloma in the United States
Lucio N Gordan, Arielle G Bensimon, Fan Mu, et al.
Current Medical Research and Opinion
|
February 18, 2026
Experiences with real-world teclistamab administration in community and outpatient settings: a mixed-methods study of hematology providers
Benjamin Derman, Jane Jijun Liu, Nicholas Bouchard, et al.
British Journal of Haematology
|
October 21, 2021
Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study
Alessandra Larocca, Xavier Leleu, Cyrille Touzeau, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 21) with videos related to
Sort By:
Page
of 3
Transplantation Proceedings
|
December 28, 2021
Can Donor-Derived Cell-Free DNA Detect Graft-Versus-Host Disease in Solid Organ Transplantation: A Case Report
Michael D Williams, Joshua Thomas, Agne Paner, et al.
Hemasphere
|
March 2, 2023
Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-related Quality of Life for Patients With Relapsed/Refractory Multiple Myeloma: Final Data From the Phase 2 ELOQUENT-3 Trial
Katja Weisel, Meletios A Dimopoulos, Jesús San-Miguel, et al.
Current Medical Research and Opinion
|
May 15, 2024
Panel Interview of ONcology practices with Emergent Experience of teclistamab in the Real world: the TecPIONEER Study
Benjamin A Derman, Meaghan Roach, Dee Lin, et al.
Investigational New Drugs
|
March 4, 2020
Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma
Eric K Rowinsky, Agne Paner, Jesus G Berdeja, et al.
Journal of Clinical Apheresis
|
June 10, 2020
Trends in the use of therapeutic plasma exchange in multiple myeloma
Binod Dhakal, Sophie Miller, Lisa Rein, et al.
NPJ Genomic Medicine
|
March 18, 2021
Non-secretory multiple myeloma with unusual TFG-ALK fusion showed dramatic response to ALK inhibition
Ashiq Masood, Trevor Christ, Samia Asif, et al.
Cancers
|
April 14, 2025
Real-World Evidence Evaluating Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Systematic Literature Review
Benjamin Derman, Carlyn Tan, Ian Steinfield, et al.
Journal of Medical Economics
|
June 11, 2025
Cost per responder for teclistamab and elranatamab in relapsed or refractory multiple myeloma in the United States
Lucio N Gordan, Arielle G Bensimon, Fan Mu, et al.
Current Medical Research and Opinion
|
February 18, 2026
Experiences with real-world teclistamab administration in community and outpatient settings: a mixed-methods study of hematology providers
Benjamin Derman, Jane Jijun Liu, Nicholas Bouchard, et al.
British Journal of Haematology
|
October 21, 2021
Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study
Alessandra Larocca, Xavier Leleu, Cyrille Touzeau, et al.
Page
of 3